The liver cancer patients with upregulated RasGRP1 expression exhibited significantly smaller tumour sizes (Fig. 7f), lower γ-glutamyl transferase levels (Fig. 7g) and longer total survival (Fig. 7h) than the liver cancer patients with downregulated RasGRP1 expression. This evidence concerns the gene RASGRP1 and liver cancer.